Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03651037
Other study ID # THRIVORSBH-01
Secondary ID R43CA224412
Status Completed
Phase N/A
First received
Last updated
Start date January 21, 2019
Est. completion date March 1, 2020

Study information

Verified date August 2020
Source Thrivors Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cancer treatment-induced bone loss and the subsequent risk of fractures in both men and women impacts not just survivors' quality of life, but is also a significant burden on national health care. Clinical studies have reported that moderate-intensity resistance exercises prevent a decline in bone health in female cancer survivors, and that strength training may reduce complications associated with cancer such as fatigue, muscle wasting, and bone loss. Unfortunately, only a small percentage of women who have had cancer, engage in and adhere to a strength training exercise routine.

The investigators have developed an internet-based application, Thrivors, that guides cancer survivors through exercise routines with light-to-moderate strength training in the home setting, and connects them to survivorship resources. In this Phase I proposal, the investigators will develop and deploy an enhanced version, Thrivors+BH, that disseminates resistance training exercises specifically impacting bone health (BH), integrated with video-based interactive feedback and tracking of adherence to exercise routines.

The goal is to validate Thrivors+BH as a novel tool to bridge the gaps between cancer survivorship, physical activity, value-based care and health care organizations (providers and payers), to positively impact bone health in breast cancer survivors.


Description:

Significance: Cancer treatment-induced bone loss and the subsequent risk of fractures in both men and women is a significant burden on national health care. The number of cancer survivors in the United States will reach 18 million by 2022 and by 2025, the projected burden of osteoporosis is $25.3 billion. Cancer patients treated with medications that lower hormone levels face an increased risk of fractures. Clinical studies report that moderate- intensity resistance exercises prevent a decline in bone health in female cancer survivors, and that strength training may reduce complications associated with cancer such as fatigue, muscle wasting, and bone loss. Unfortunately, only a small percentage of female cancer survivors engage in and adhere to a strength training exercise routine. Several factors account for this low level of engagement such as poor awareness of the benefits of exercise, lack of motivation, and the lack of affordable and easily accessible exercise programs designed for cancer survivors. Internet-based self-managed programs of exercises and guidance can potentially address these problems, and can be scaled for broader dissemination.

Innovation: The Thrivors internet-based platform seeks to shift the current paradigm of poor adherence to exercise by providing an affordable and accessible means of improving outcomes for cancer survivors. The proposed product, Thrivors+BH, will be a first-of-its-kind offering of clinically validated bone health exercises that can be customized to a cancer survivor's pain and energy levels, with several novel interactive feedback features. The product will also have supportive modules for connecting with a community of other users, mindfulness training, nutritional advice and a repository of educational information. The Thrivors platform is scalable, device-agnostic, and allows analysis of de-identified usage data. With commercialization potential for healthcare providers and health insurance payers, Thrivors provides a value-based care delivery model focused on outcomes. There are multiple important physiologic and psychosocial secondary conditions that could be positively impacted by the Thrivors platform. For this specific application, the investigators will focus on adherence to bone health exercises.

Hypothesis: The investigators hypothesized that breast cancer survivors' adherence to an exercise regimen for bone health can be improved by enhancing the interactive and customizable features of a cloud-based, device-agnostic delivery method. To test the hypothesis and to establish the technical feasibility of the product, the investigators propose the following specific aims:

Specific Aim 1: Develop an enhanced participant experience platform for bone health-specific exercises.

For Thrivors+BH, a module will be developed for participants to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, participants will be able upload and send videos of themselves exercising for feedback and assessment. A Thrivors Basic version that lacks customization and video content will be developed. Both versions will contain bone health educational content, mindfulness and nutrition resources. Milestones: Over a 2-month period, development, usability testing (assessing content, features, input controls, navigational ease and click-through capabilities) and refinement will be completed, to enable deployment in a randomized clinical trial.

Specific Aim 2: Measure participant adherence and engagement. The two versions of the platform will be deployed in a 20-week, two-arm randomized controlled trial of 50 breast cancer survivors. Adherence to exercise sessions (primary outcome) and platform usage will be measured by platform software, while user engagement (secondary outcomes) will be assessed by surveys. Milestones: Differences between primary and secondary outcomes for the control and intervention groups will be evaluated. Usage statistics, motivational responses and user feedback will be used to further refine platform features and content.

The outcomes of this study will help validate the utility of the Thrivors platform in improving cancer survivors' adherence and engagement to exercise routines that positively impact post-treatment recovery. In the near-term, the findings will inform the design of a 12-month Phase II study to evaluate changes in biomarkers of bone health. In the longer term, the project aligns with the business goal to disseminate the Thrivors platform to a larger population of male and female cancer survivors across ethnic/racial minority groups, rural populations, and low socioeconomic status groups. The project also aligns with the mission of the NCI to develop innovative technology and service delivery models that increase the adoption, uptake, and sustainability of evidence-based interventions to improve public health.


Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date March 1, 2020
Est. primary completion date March 1, 2020
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Female participants diagnosed at 40 - 70 years with non-metastatic breast cancer.

- Able to provide written informed consent.

- Completed chemotherapy, undergoing adjuvant hormonal therapy.

- Not currently on a prescribed exercise plan and cleared for exercise by physician.

- Access to a smart phone (with a data plan), tablet, or computer (with internet access).

- Able and willing to comply with the protocol, including completion of all surveys.

Exclusion Criteria:

- Less than 4 weeks post-surgery.

- Diagnosis of osteoporosis.

- Currently participating in two or more 30-min. sessions/week of resistance or impact exercises.

- Specific condition(s) or diagnosis, both physical or psychological, or physical exam finding that precludes participation in a physical exercise program.

- Participant has hemodynamically significant heart disease (e.g., heart failure) or an arrhythmic heart condition requiring medical therapy.

- Employees or family members of the investigator, study site, or sponsor directly involved with study management.

- Participants who, in the opinion of the primary investigator, should not participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Thrivors+BH
Digital health platform for breast cancer patients that measures adherence and engagement.

Locations

Country Name City State
United States Thrivors Inc Saint Paul Minnesota

Sponsors (4)

Lead Sponsor Collaborator
Thrivors Inc Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI), Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants to complete exercise sessions and surveys Changes in baseline from exercise naive to exercise activated as well as improvements in well-being survey, patient activation measures, and bone health awareness 20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2